CA-EYENUK
16.5.2019 09:07:04 CEST | Business Wire | Press release
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1
The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt System can free eye care specialists to focus on sight-saving treatment rather than screening for DR.
At Diabetes Center Mergentheim, more than 20,000 patients with diabetes are seen each year by diabetes care specialists. Before adopting the EyeArt System, patients would be referred to ophthalmologists outside of the clinic. This process placed undue burden on patients, and often they would never get the necessary screening.
“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System is allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”
About 7.5 million people in Germany have diabetes mellitus2 , with over 2,500 patients going blind due to diabetic retinopathy each year. German guidelines recommend at-risk patients be screened annually, but this can be difficult with the shortage of eye doctors. By incorporating the EyeArt System into their clinic, Diabetes Center Mergentheim has addressed a serious complication associated with diabetes — the center now screens 10 to 15 patients per day for this vision-threatening condition.
“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.3 It is estimated that one-third of all patients with diabetes will develop DR,4 making it the leading cause of vision loss in working-age adults.5
While DR screening is recommended for all diabetic patients, less than half get screened annually1 , even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,130 to 1 in Germany6 , there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving an annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.
About the EyeArt AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half million patient visits globally with over 2 million images collected in real-world clinical environments. The EyeArt System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
EyeArt is a registered trademark of Eyenuk Inc.
____________________
| 1 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 2 |
International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. http://www.idf.org/diabetesatlas |
|
| 3 |
https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611 |
|
| 4 | Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909 | |
| 5 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 6 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005207/en/
Contact:
Media Contact: Capwell Communications Ida Yenney ida@capwellcomm.com 949-999-3303
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Welcomes Meta Platforms, Inc. and Alibaba Group to the Video Distribution Patent Pool3.7.2026 01:00:00 CEST | Press release
Access Advance LLC today announced that Meta Platforms, Inc., one of the world's largest distributors of video content across its Facebook, Instagram, Threads, and WhatsApp services, has joined the Video Distribution Patent Pool (VDP Pool) as a Licensee. Meta also joined both the HEVC Advance and VVC Advance pools as a Licensee. Alibaba Group, whose video infrastructure spans a wide range of video-based services across e-commerce, entertainment, and digital media platforms, was also announced as a VDP Pool Licensee this week. Meta and Alibaba joining the VDP Pool further reinforces the program’s market leading position in resolving the licensing issues around the use of modern video codecs, including VP9, AV1, HEVC and VVC, across all the diverse business models of internet video streaming. "A significant U.S.-based company like Meta joining as a Licensee is a milestone moment for the content distribution business and the VDP Pool," said Peter Moller, CEO of Access Advance. "Meta reach
Kioxia Commences Sample Shipments of 10th-Generation BiCS FLASH™ Devices Delivering High Performance, High Capacity and Low Power Consumption3.7.2026 01:00:00 CEST | Press release
Production planned at Fab2 of Kitakami Plant Kioxia Corporation, a world leader in memory solutions, today announced that it has commenced sample shipments of 1Tb (terabit) Triple-Level-Cell (TLC) memory devices utilizing its 10th-generation BiCS FLASH™ 3D flash memory technology.1 These will be primarily integrated into the company’s enterprise and data center SSDs, strengthening Kioxia’s lineup to meet the growing demand for AI storage, which requires higher performance, higher capacity, and lower power consumption. These new products will be manufactured using state-of-the-art equipment at Kioxia’s Kitakami Plant Fab2 facility in Iwate Prefecture, Japan. By leveraging innovative CMOS directly Bonded to Array (CBA) technology2 and On-Pitch Select Gate Drain (OPS) technology,3 both adopted since the 8th-generation BiCS FLASH™, the 10th-generation technology achieves a NAND interface speed of 4.8 Gb/s,4 a 33% improvement over the 8th generation. Bit density has increased by 59% by stac
Bending Spoons S.p.A. announces closing of initial public offering2.7.2026 20:35:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the closing of its initial public offering of an aggregate of 57,971,015 of its ordinary shares, at an initial public offering price of $29.00 per share. The offering consisted of 34,398,640 shares sold by Bending Spoons and 23,572,375 shares sold by certain selling shareholders (the “Selling Shareholders”). The gross proceeds from the offering to Bending Spoons, before deducting underwriting discounts and commissions and other offering expenses, was approximately $953,917,285.50. Bending Spoons did not receive any proceeds from the sale of shares by the Selling Shareholders. Bending Spoons’ ordinary shares began trading on the Nasdaq Global Select Market on July 1, 2026 under the ticker symbol “BSP”. Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP
Strategic Partnership Between Record Asset Management and Admicasa2.7.2026 19:00:00 CEST | Press release
RAM Swiss Holding AG announces a strategic partnership with Admicasa Holding AG (Admicasa). RAM Swiss Holding AG is a subsidiary of LSE-listed Record Financial Group (Record) and part of the Record Asset Management (RAM) group of companies. The partnership is a milestone in the growth of Admicasa and marks an important step in the continued expansion of Record’s private markets platform. Subject to regulatory approval, the agreement, signed on 1st July 2026, provides RAM Swiss Holding AG with a 50% participation in the Admicasa Fondsleitung AG, part of Admicasa, and establishes a long-term partnership to develop investment opportunities in the Swiss and Global real estate market with a plan to expand into other asset classes in the medium term. RAM is the European asset management arm of Record, the LSE-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign
IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange2.7.2026 16:47:00 CEST | Press release
IQM begins trading on Nasdaq Global Select Market under the ticker symbol “IQMX” Company enters next phase of growth as a publicly traded leader in full-stack superconducting quantum computing IQM maintains a strong pro forma cash position of EUR 337 million IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, today became a publicly traded company following the completion of its business combination with Real Asset Acquisition Corp. (“RAAQ”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702960460/en/ IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange The company’s American Depositary Shares begin trading today on the Nasdaq Global Select Market under the ticker symbol “IQMX”. The listing marks a major milestone for IQM establishing the company as the first European quan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom